Low Annexin A1 expression predicts benefit from induction chemotherapy in oral cancer patients with moderate or poor pathologic differentiation grade

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Zhu, Dong wang ^a   Liu, Ying ^a   Yang, Xiao ^a   Yang, Cheng zhe ^a   Ma, Jie ^a   Yang, Xi ^a   Qiao, Jin ke ^a   Wang, Li zhen ^a   Li, Jiang ^a   Zhang, Chen ping ^a   Zhang, Zhi yuan ^a   Zhong, Lai ping ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Annexin A1; Induction chemotherapy; Oral squamous cell carcinoma

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; LIPOCORTIN 1; TUMOR MARKER; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; CANCER CELL; CANCER GRADING; CANCER PROGNOSIS; CANCER RISK; CELL MEMBRANE; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; DISEASE FREE SURVIVAL; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; INDUCTION CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; TISSUE DIFFERENTIATION; TUMOR BIOPSY; BIOSYNTHESIS; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; CLINICAL TRIAL; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MOUTH NEOPLASMS; MULTIMODALITY CANCER THERAPY; ORAL SURGERY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL;

ANNEXIN A1; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INDUCTION CHEMOTHERAPY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM GRADING; ORAL SURGICAL PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY; TUMOR MARKERS, BIOLOGICAL;

EID: 84879071460     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-301     Document Type: Article

References (37)

1. Neville BW, Day TA. Oral cancer and precancerous lesions. CA Cancer J Clin 2002, 52:195-215. 10.3322/canjclin.52.4.195, 12139232.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108. 10.3322/canjclin.55.2.74, 15761078.
3. Kademani D, Bell RB, Bagheri S, Holmgren E, Dierks E, Potter B, Homer L. Prognostic factors in intraoral squamous cell carcinoma: the influence of histologic grade. J Oral Maxillofac Surg 2005, 63:1599-1605. 10.1016/j.joms.2005.07.011, 16243176.
4. Arduino PG, Carrozzo M, Chiecchio A, Broccoletti R, Tirone F, Borra E, Bertolusso G, Gandolfo S. Clinical and histopathologic independent prognostic factors in oral squamous cell carcinoma: a retrospective study of 334 cases. J Oral Maxillofac Surg 2008, 66:1570-1579. 10.1016/j.joms.2007.12.024, 18634942.
5. Bell RB, Kademani D, Homer L, Dierks EJ, Potter BE. Tongue cancer: Is there a difference in survival compared with other subsites in the oral cavity?. J Oral Maxillofac Surg 2007, 65:229-236. 10.1016/j.joms.2005.11.094, 17236926.
6. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM, Haddad RI, TAX 324 Study Group Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007, 357:1705-1715. 10.1056/NEJMoa070956, 17960013, TAX 324 Study Group.
7. Vermorken BJ, Remenar E, Herpen VC, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den-Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL, EORTC 24971/TAX 323 Study Group Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007, 357:1695-1704. 10.1056/NEJMoa071028, 17960012, EORTC 24971/TAX 323 Study Group.
8. Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, Tan M, Fasciano J, Sammartino DE, Posner MR, TAX 324 Study Group Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 2011, 12:153-159. 10.1016/S1470-2045(10)70279-5, 21233014, TAX 324 Study Group.
9. Zhong LP, Zhang CP, Ren GX, Guo W, William WN, Sun J, Zhu HG, Tu WY, Li J, Cai YL, Wang LZ, Fan XD, Wang ZH, Hu YJ, Ji T, Yang WJ, Ye WM, Li J, He Y, Wang YA, Xu LQ, Wang BS, Kies MS, Lee JJ, Myers JN, Zhang ZY. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol 2013, 31:744-751. 10.1200/JCO.2012.43.8820, 23129742.
10. Lim LH, Pervaiz S. Annexin 1: the new face of an old molecule. FASEB J 2007, 21:968-975. 10.1096/fj.06-7464rev, 17215481.
11. Petrella A, Festa M, Ercolino SF, Zerilli M, Stassi G, Solito E, Parente L. Annexin-1 downregulation in thyroid cancer correlates to the degree of tumor differentiation. Cancer Biol Ther 2006, 5:643-647. 10.4161/cbt.5.6.2700, 16627980.
12. Wang LD, Yang YH, Liu Y, Song HT, Zhang LY, Li PL. Decreased expression of annexin A1 during the progression of cervical neoplasia. J Int Med Res 2008, 36:665-672. 10.1177/147323000803600407, 18652761.
13. Hu N, Flaig MJ, Su H, Shou JZ, Roth MJ, Li WJ, Wang C, Goldstein AM, Li G, Emmert-Buck MR, Taylor PR. Comprehensive characterization of annexin I alterations in esophageal squamous cell carcinoma. Clin Cancer Res 2004, 10:6013-6022. 10.1158/1078-0432.CCR-04-0317, 15447985.
14. Garcia Pedrero JM, Fernandez MP, Morgan RO, Morgan RO, Herrero Zapatero A, Gonzalez MV, Suarez Nieto C, Rodrigo JP. Annexin A1 down-regulation in head and neck cancer is associated with epithelial differentiation status. Am J Pathol 2004, 164:73-79. 10.1016/S0002-9440(10)63098-2, 1602219, 14695321.
15. Nomura H, Uzawa K, Yamano Y, Fushimi K, Nakashima D, Kouzu Y, Kasamatsu A, Ogawara K, Shiiba M, Bukawa H, Yokoe H, Tanzawa H. Down-regulation of plasma membranous Annexin A1 protein expression in premalignant and malignant lesions of the oral cavity: correlation with epithelial differentiation. J Cancer Res Clin Oncol 2009, 135:943-949. 10.1007/s00432-008-0530-z, 19101730.
16. Shen D, Nooraie F, Elshimali Y, Lonsberry V, He J, Bose S, Chia D, Seligson D, Chang HR, Goodglick L. Decreased expression of annexin A1 is correlated with breast cancer development and progression as determined by a tissue microarray analysis. Hum Pathol 2006, 37:1583-1591. 10.1016/j.humpath.2006.06.001, 16949910.
17. Kang JS, Calvo BF, Maygarden SJ, Caskey LS, Mohler JL, Ornstein DK. Dysregulation of annexin I protein expression in high-grade prostatic intraepithelial neoplasia and prostate cancer. Clin Cancer Res 2002, 8:117-123.
18. Yom CK, Han W, Kim SW, Kim HS, Shin HC, Chang JN, Koo M, Noh DY, Moon BI. Clinical significance of annexin A1 expression in breast cancer. J Breast Cancer 2011, 14:262-268. 10.4048/jbc.2011.14.4.262, 3268921, 22323911.
19. Wang LP, Bi J, Yao C, Li XX, Wang SM, Li ZL, Zhang DY, Wang M, Chang GQ. Annexin A1 expression and its prognostic significance in human breast cancer. Neoplasma 2010, 57:253-259. 10.4149/neo_2010_03_253, 20353277.
20. Lin CY, Jeng YM, Chou HY, Li QQ, Chen ZC. Nuclear localization of annexin A1 is a prognostic factor in oral squamous cell carcinoma. J Surg Oncol 2008, 97:544-550. 10.1002/jso.20992, 18297688.
21. Liu YF, Zhang PF, Li MY, Li QQ, Chen ZC. Identification of annexin A1 as a proinvasive and prognostic factor for lung adenocarcinoma. Clin Exp Metastasis 2011, 28:413-425. 10.1007/s10585-011-9380-1, 21365324.
22. Biaoxue R, Xiling J, Shuanying Y, Wei Z, Xiguang C, Jinsui W, Min Z. Upregulation of Hsp90-beta and annexin A1 correlates with poor survival and lymphatic metastasis in lung cancer patients. J Exp Clin Cancer Res 2012, 31:70. 10.1186/1756-9966-31-70, 3444906, 22929401.
23. Wang KL, Wu TT, Resetkova E, Wang H, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Hamilton SR, Albarracin CT. Expression of annexin A1 in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Clin Cancer Res 2006, 12:4598-4604. 10.1158/1078-0432.CCR-06-0483, 16899607.
24. Li CF, Shen KH, Huang LC, Huang HY, Wang YH, Wu TF. Annexin-I overexpression is associated with tumour progression and independently predicts inferior disease-specific and metastasis-free survival in urinary bladder urothelial carcinoma. Pathology 2010, 42:43-49. 10.3109/00313020903434405, 20025479.
25. Bai XF, Ni XG, Zhao P, Liu SM, Wang HX, Guo B, Zhou LP, Liu F, Zhang JS, Wang K, Xie YQ, Shao YF, Zhao XH. Overexpression of annexin 1 in pancreatic cancer and its clinical significance. World J Gastroenterol 2004, 10:1466-1470.
26. Guzman-Aranguez A, Olmo N, Turnay J, Lecona E, Perez-Ramos P, Lopez de Silanes I, Lizarbe MA. Differentiation of human colon adenocarcinoma cells alters the expression and intracellular localization of annexins A1, A2, and A5. J Cell Biochem 2005, 94:178-193. 10.1002/jcb.20293, 15526283.
27. Masaki T, Tokuda M, Ohnishi M, Watanabe S, Fujimura T, Miyamoto K, Itano T, Matsui H, Arima K, Shirai M, Maeba T, Sogawa K, Konishi R, Taniguchi K, Hatanaka Y, Hatase O, Nishioka M. Enhanced expression of the protein kinase substrate annexin in human hepatocellular carcinoma. Hepatology 1996, 24:72-81.
28. Chuthapisith S, Bean BE, Cowley G, Eremin JM, Samphao S, Layfield R, Kerr ID, Wiseman J, El-Sheemy M, Sreenivasan T, Eremin O. Annexins in human breast cancer: Possible predictors of pathological response to neoadjuvant chemotherapy. Eur J Cancer 2009, 45:1274-1281. 10.1016/j.ejca.2008.12.026, 19171478.
29. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van-Glabbeke M, van-Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216. 10.1093/jnci/92.3.205, 10655437.
30. Licitra L, Grandi C, Guzzo M, Mariani L, Lo Vullo S, Valvo F, Quattrone P, Valagussa P, Bonadonna G, Molinari R, Cantu G. Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial. J Clin Oncol 2003, 21:327-333. 10.1200/JCO.2003.06.146, 12525526.
31. Barnes L, Eveson JW, Reichart P, Sidransky D. World Health Organization Classification of Tumours. Pathology and Genetics of Head and Neck Tumours 2005, 168-175. Lyon: IARC Press.
32. Zhong LP, Wei KJ, Yang X, Pan HY, Wang LZ, Zhang ZY. Overexpression of Galectin-1 is positively correlated with pathologic differentiation grade in oral squamous cell carcinoma. J Cancer Res Clin Oncol 2010, 136:1527-1535. 10.1007/s00432-010-0810-2, 20157731.
33. Zhang L, Yang X, Pan HY, Zhou XJ, Li J, Chen WT, Zhong LP, Zhang ZY. Expression of growth differentiation factor 15 is positively correlated with histopathological malignant grade and in vitro cell proliferation in oral squamous cell carcinoma. Oral Oncol 2009, 45:627-632. 10.1016/j.oraloncology.2008.07.017, 18805046.
34. Zhang L, Yang X, Zhong LP, Zhou XJ, Pan HY, Wei KJ, Li J, Chen WT, Zhang ZY. Decreased expression of Annexin A1 correlates with pathologic differentiation grade in oral squamous cell carcinoma. J Oral Pathol Med 2009, 38:362-370.
35. Wang Y, Serfass L, Roy MO, Wong J, Bonneau AM, Georges E. Annexin-I expression modulates drug resistance in tumor cells. Biochem Biophys Res Commun 2004, 314:565-570. 10.1016/j.bbrc.2003.12.117, 14733945.
36. Zhong LP, Zhu DW, William WN, Liu Y, Ma J, Yang CZ, Yang X, Wang LZ, Li J, Myers JN, Lee JJ, Zhang CP, Zhang ZY. Elevated cyclin D1 expression is predictive for a benefit from TPF induction chemotherapy in oral squamous cell carcinoma patients with advanced nodal disease. Mol Cancer Ther 2013, 12:1112-1121. 10.1158/1535-7163.MCT-12-1013, 23515614.
37. Cullen KJ, Schumaker L, Nikitakis N, Goloubeva O, Tan M, Sarlis NJ, Haddad RI, Posner MR. Beta-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial. J Clin Oncol 2009, 27:6222-6228. 10.1200/JCO.2009.23.0953, 19917838.